Answers are grounded in this paper and cite their sources.
Circulating tumor cells and cancer-associated fibroblasts (CTCs/cCAFs) are promising biomarkers, but their rarity and heterogeneity make identification labor-intensive, even with standardized technologies such as imaging flow cytometry (imFC). Here, we developed a human-in-the-loop deep-learning workflow addressing this bottleneck by prioritizing candidate cells for expert review. A model trained on five-channel imFC-images and expert-annotated breast cancer reference CTCs/cCAFs libraries was evaluated in 59 patients with 5 cancer types and 6 healthy donors at two centers/devices. In peripheral blood, the model detected 443/490 CTCs/cCAFs among 7.8 million events, with 54.8 false positives/100,000 events. Reviewing 50 prioritized candidates/sample reached the predefined threshold in eligible samples, taking 2min 15sec/sample versus an estimated 30min manually. In tumor-draining vein blood, 1,200/1,678 CTCs/cCAFs were detected. Detection of ≥1CTC was associated with lymph node and/or distant metastases (p=0.016). This workflow may facilitate scalable imFC analysis with expert verification. Multicenter studies are needed to confirm generalizability and clinical relevance.
No takes yet. Share an insight, caveat, or question.
Świeżewski et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: